Heritage Provider Network
VC Fund
Northridge, United States
Heritage Provider Network (HPN) is a limited Knox-Keene licensed organization in California that provides affordable quality care to its members. Through innovative programs and services designed specifically for the managed care environment, HPN and its medical groups have been successful in delivering the goals it set out to achieve whileestablishing long-standing, favorable provider relationships.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Heritage Provider Network invests in
Stages Heritage Provider Network invests in
Countries Heritage Provider Network invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Richard Merkin
|
|||
Investment Focus
Industry
- Biotechnology 9 (64%)
- Health Care 7 (50%)
- Genetics 3 (21%)
- Life Science 3 (21%)
- Medical Device 3 (21%)
Stage
- Series A 5 (36%)
- Series C 4 (29%)
- Seed 2 (14%)
- Series B 2 (14%)
Country
- United States 10 (71%)
- China 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Richard Merkin
Founder and CEO
|
Founder and CEO | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Celsius Therapeutics
|
Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $83M / Series B / Mar 24, 2022 | |
InterVenn
|
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $201M / Series C / Aug 02, 2021 | |
Circumvent
|
Circumvent Pharmaceuticals is seeking to address the significant unmet need of neurodegenerative disease patients. Circumvent is targeting heritable forms of neurodegeneration to enable drug discovery and development in both rare and common forms of neurodegenerative disease. Circumvent is funded by NIH/NINDS, YC Bio, Heritage ProviderNetwork, the Longevity Fund, and additional investors. | $4.1M / Seed / Dec 09, 2020 | |
RubiconMD
|
RubiconMD is a web-based eConsult service that enables primary care providers to quickly and easily discuss their cases with top specialists, so they can provide better care—improving the patient experience and reducing costs. RubiconMD was founded in 2013 by Gil Addo, Carlos Reines, and Julien Pham. It is headquartered in New York, New York. | $18M / Series C / Mar 10, 2020 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $3.5M / Seed / Mar 13, 2019 | |
Alphamab Oncology
|
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipelinein oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally. | $100M / Series A / Nov 16, 2018 | |
Glympse Bio
|
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering. | $22M / Series A / Oct 09, 2018 | |
Digital Diagnostics
|
Digital Diagnostics, formerly IDx, is a pioneering AI diagnostics company founded with a mission to transform the quality, accessibility, equity, and affordability of healthcare worldwide through the application of technology in the medical diagnosis and treatment process. Founded by Michael Abramoff, MD, PhD, a fellowship-trained retinaspecialist, neuroscientist, and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build an autonomous AI platform that makes clinical decisions without human intervention, removing the diagnostic burden of common diseases from specialists. Digital Diagnostics is paving the way for autonomous AI diagnosis to become the new standard of care, helping to democratize healthcare and close care gaps to improve patient outcomes. By working closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders, Digital Diagnostics is working with the healthcare system to enable the continued adoption of autonomous AI. | $32.6M / Series A / Sep 27, 2018 | |
|
Celsius Therapeutics
|
Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $65M / Series A / May 15, 2018 | |
|
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $2.4M / Seed / Feb 08, 2018 | |
| See all 14 investments → | |||
Co-Investors
Cambia Health Solutions
2 deals together
Digitalis Ventures
2 deals together
Google Ventures
2 deals together
Innovation Endeavors
2 deals together
Mitsui & Co
2 deals together
Optum Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Heritage Provider Network invest in?
Heritage Provider Network invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series A and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Heritage Provider Network?
Public channels for Heritage Provider Network include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Heritage Provider Network?
The team at Heritage Provider Network includes Richard Merkin (Founder and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
